Why the study?
Optimizing unfractionated heparin therapy requires precise activated partial thromboplastin time monitoring, and the impact of clinical pharmacists on achieving target levels needed evaluation.
Does clinical pharmacist intervention improve the achievement of target aPTT levels in patients receiving unfractionated heparin in a cardiac care unit?
Does clinical pharmacist intervention improve the achievement of target aPTT levels in patients receiving unfractionated heparin in a cardiac care unit?
Clinical pharmacist interventions in the cardiac care unit significantly improve the achievement of therapeutic aPTT levels in patients receiving unfractionated heparin.
Pharmacist involvement may aid aPTT target attainment during UFH therapy; leaves open whether it improves outcomes in randomized settings.
Background : Unfractionated heparin (UFH) requires precise monitoring, primarily via activated partial thromboplastin time (aPTT), to achieve therapeutic anticoagulation and minimize complications. Optimizing UFH therapy demands robust monitoring strategies and collaborative involvement of healthcare professionals, particularly pharmacists. Objective : This study aimed to evaluate aPTT levels in patients receiving UFH and determine the impact of clinical pharmacists on achieving target aPTT in a cardiac care unit (CCU). Patients and methods : A prospective observational study was conducted in the CCU of Baghdad Teaching Hospital from February 2023 to January 2024, enrolling patients prescribed UFH. Results : Of 307 patients, only 21% (n = 65) initially reached therapeutic aPTT levels. Notably, only 1 of 47 patients receiving subcutaneous UFH achieved target aPTT (P = 0.009). Clinical pharmacists performed 80 interventions, resulting in a statistically significant improvement in mean aPTT from 44.1 ± 24.8 to 46.7 ± 24 (P < 0.001). This increased the percentage of patients within the therapeutic range from 21% (n = 65) to 29% (n = 90). Conclusion : Clinical pharmacist interventions significantly improved aPTT targeting for UFH in the CCU, increasing therapeutic achievement rates despite initially suboptimal levels and highlighting their value in optimizing anticoagulation therapy.
No takes yet. Share an insight, caveat, or question.
Sami et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: